Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 4

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
     1,393 
  
    Accounts payable and accrued liabilities – related parties 
     78  
     21 
  
    Deferred liabilities 
     (37) 
     31 
  
    Operating lease liabilities 
     (8) 
     (6)
  
    Net cash used in operating activities 
     (6,824) 
     (7,476)

    CASH FLOWS FROM FINANCING ACTIVITIES: 

    Sale of common stock for cash 
     5,273  
     - 
  
    Exercise of warrants for cash 
     1  
     - 
  
    Repayments of debt 
     -  
     (2,500)
  
    Net provided by (used in) financing activities 
     5,274  
     (2,500)

    Impact on cash from foreign currency translation 
     (35) 
     130 

    NET DECREASE IN CASH AND CASH EQUIVALENTS 
     (1,585) 
     (9,846)
  
    CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 
     20,922  
     35,848 
  
    CASH AND CASH EQUIVALENTS AT END OF PERIOD 
    $19,337  
    $26,002 

    SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: 

    Cash paid for income taxes 
    $-  
    $- 
  
    Cash paid for interest expense 
    $-  
    $302 

The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.

5

INMUNE BIO INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND DESCRIPTION
OF BUSINESS

INmune Bio Inc. (the “Company” or
“INmune Bio”) was organized in the State of Nevada on September 25, 2015 and is a clinical stage biotechnology pharmaceutical
company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning
normally and contributing to the patient’s disease. INmune Bio has three product platforms. The DN-TNF product platform utilizes
dominant-negative technology to selectively neutralize soluble TNF, a